Cipla has launched Yurpeak® (Tirzepatide) in India, a one-weekly injectable therapy for managing obesity and type 2 diabetes. Cipla has rights to distribute and promote Yurpeak®. It is indicated as an adjunct to diet and exercise for the treatment of Type 2 diabetes and chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity. Yurpeak® will be available in six strengths.
Yurpeak® Launch Details
Cipla announced the launch of Yurpeak® (Tirzepatide), a once-weekly injectable treatment option for obesity and type 2 diabetes in India, effective December 10, 2025. Cipla now possesses the distribution and promotional rights for Yurpeak®, marking the second brand of Lilly’s tirzepatide in India following regulatory approval.
Therapeutic Use and Availability
Tirzepatide functions as the first dual agonist, targeting both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. It’s prescribed alongside diet and exercise for adults with Type 2 diabetes, and for chronic weight management in individuals with obesity (BMI ≥ 30) or those overweight (BMI ≥ 27) who also have a weight-related comorbidity.
Dosage and Strengths
Yurpeak® will be available via prescription in the KwikPen® device format in six different strengths: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg. This range allows for precise and convenient dosing tailored to the patient’s needs.
Cipla’s Perspective
Achin Gupta, Global Chief Operating Officer, Cipla Limited, stated that the launch of Yurpeak® marks a transformative moment in the fight against obesity and type 2 diabetes, two of India’s chronic conditions with a heavy burden. Cipla is entering this space with expertise and commitment.
Access and Distribution
The launch of Yurpeak® in India will improve access to tirzepatide. Cipla will prioritize making it available across India, utilizing its distribution network and market insights to drive reach and accessibility. Lilly will handle the manufacturing and supply of Yurpeak® to Cipla, and the price will be the same as Mounjaro®.
Patient Support
Cipla will also introduce patient education and support programs to complement the launch of Yurpeak®. These programs will include guidance on dosing, self-administration, and safe usage of the therapy.
Source: BSE